Indication name: Osteosarcoma
Osteosarcoma Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019
To 2030
Osteosarcoma is not a common
cancer. Each year, about 1,000 new cases of osteosarcoma are diagnosed in the
United States.
Competitive landscape of Osteosarcom
includes country specific approved as well as pipeline therapies. Any asset/
product specific designation or review and Accelerated Approval are being
tracked and supplemented with analyst commentary.
Market Forecast: Patient Based Forecast Model (MS. Excel Based
Automated Dashboard) which Data Inputs with sourcing , Market Event and Product
Event , Country specific Forecast Model , Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing
scenario , Summary and Insights.
KOL insights across 8 MM
market from center of Excellence/ Public/ Private hospitals participated in the
study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
1. Drug: ALMB-0168 AlaMab Therapeutics (Shanghai)
Inc. Phase 2
2. Drug: Lenvatinib Merck Sharp & Dohme Corp. Phase 2
3. Drug: ZN-c3 K-Group Beta Phase 2
4. Drug: ZKAB001 5mg/kg Lee's Pharmaceutical Limited Phase 2
5. Drug: Calcium Folinate Isofol Medical AB Phase 2
6. Drug: Lenvatinib Eisai Limited Phase 2
7. Drug: Cisplatin liposomal Insmed Incorporated Phase 2
8. Drug: Inhaled Lipid Cisplatin
(ILC) Eleison Pharmaceuticals
LLC. Phase 2
9. Drug: Nivolumab Bristol-Myers Squibb Phase 2
10.Drug: Apatinib Jiangsu HengRui Medicine Co., Ltd. Phase 2
11. Drug: Sirolimus combined with
CP, MT and ZA Reliable Cancer
Therapies Phase 1
12. Drug: Sirolimus combined with CP, MT and
ZA Pfizer Phase 1
13. Drug: Olaparib AstraZeneca Phase 2
14. Drug: M6620 EMD Serono Phase 2
15. Drug: IBI188 Innovent Biologics (Suzhou) Co.
Ltd. Phase 1
16. Drug: GM-CSF Y-mAbs Therapeutics Phase 2
17. Drug: CLR 131 Cellectar Biosciences, Inc. Phase 1
18. Drug: Pazopanib
Hydrochloride GlaxoSmithKline Phase 2
19. Device: ExAblate 2100 InSightec Phase 2
20. Biological: Aldesleukin Iovance Biotherapeutics, Inc. Phase 2
21. Drug: compound 31543
Calcitriol Berg, LLC Phase 1
22. Combination Product:
MASCT-I,PD1 Antibody, Apatinib SYZ
Cell Therapy Co.. Phase 1
23. Biological: CRX100 suspension
for infusion Bio Eclipse
Therapeutics Phase 1
24. Drug: cisplatin Novartis Phase 3
25. Drug: cisplatin Chugai Pharmaceutical Phase 3
26. Drug: Enoblituzumab Macro Genics Phase 1
27. Biological: CAB-AXL-ADC Bio Atla, Inc. Phase 2
28. Drug: KCP-330 Karyopharm Therapeutics Inc Phase 1
29. Drug: BAY806946 Bayer Phase 2
30. Drug: 177Lu-3BP-227 (also
called 177Lu-IPN01087) Ipsen Phase 2
31. Drug: 9-ING-41 Actuate Therapeutics Inc. Phase 2
32. Drug: Recombinant Vaccinia
GM-CSF; RAC VAC GM-CSF (JX-594)
Jennerex Biotherapeutics
Phase 1
33. Drug: Recombinant Vaccinia
GM-CSF; RAC VAC GM-CSF (JX-594)
Silla Jen, Inc. Phase 1
34. Biological: Nivolumab Nektar Therapeutics Phase 2
35. Drug: plerixafor Genzyme, a Sanofi Company Phase 2
36. Drug: Seclidemstat Salarius Pharmaceuticals, LLC Phase 1
37. Biological: Vigil Gradalis, Inc. Phase 2
38. Drug: Talazoparib Medivation, Inc. Phase 1
39. Drug: Eribulin mesilate Eisai Inc. Phase 2
40. Biological: Vigil Gradalis, Inc. Phase 3
41. Drug: TK216 Oncternal Therapeutics, Inc Phase 1
42. Drug: VAL-413 Valent
Technologies, Inc. Phase 1
43. Drug: AMG 479 Nant Cell, Inc.
Phase 2
44. Drug: Lipegfilgrastim Teva
Pharmaceutical Industries Phase 1
45. Biological: IMC-A12 (cixutumumab)
Eli Lilly and Company Phase 2
46. Drug: Gemcitabine Celgene Corporation Phase 1
47. Drug: Durvalumab MedImmune
LLC Phase 2
48. Drug: Cyclophosphamide, Topotecan,
and Bevacizumab Genentech, Inc. Phase
2"
No comments:
Post a Comment